Citation Tools
PDFRegular and young investigator award abstracts
Clinical trials in progress
323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients